Last reviewed · How we verify
Olanzapine OD Tablets 5 mg
At a glance
| Generic name | Olanzapine OD Tablets 5 mg |
|---|---|
| Also known as | Zyprexa Zydis |
| Sponsor | Dr. Reddy's Laboratories Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fasting Condition (PHASE1)
- Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olanzapine OD Tablets 5 mg CI brief — competitive landscape report
- Olanzapine OD Tablets 5 mg updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI